The impact of changing from ocrelizumab to ofatumumab on disease activity, infection and immunological parameters in patients with multiple sclerosis

被引：0
|
作者：
Montague, Turlough [1 ]
Chatterton, Sophie [1 ]
Cheung, Emily [1 ]
Thomas, Karen [1 ]
Simpson-Burke, Nicole [1 ]
Markoulis, Katherine [1 ]
Miller, Celia [1 ]
Fontes-Villalba, Ariadna [1 ]
Parratt, John [1 ]
机构：
[1] Royal North Shore Hosp, Sydney, NSW, Australia
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1715/1624
引用
收藏
页码：1084 / 1084
页数：1
相关论文
共 50 条
  • [41] Impact of Age on Multiple Sclerosis Disease Activity and Progression
    Zeydan, Burcu
    Kantarci, Orhun H.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2020, 20 (07)
  • [42] The risk of disease activity after Covid-19 infection in patients with multiple sclerosis
    Boz, Cavit
    Karahan, Serap
    Boz, Gonulden Aktoz
    Okumus, Aleyna Caglar
    Oral, Ebru
    Usta, Senanur
    Tavlioglu, Sinem
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 837 - 838
  • [43] No Evidence of Disease Activity on Ocrelizumab Treatment in Patients With Early Relapsing Multiple Sclerosis: Pooled Analysis of the Phase III OPERA Studies
    Havrdova, Eva
    Hauser, Stephen
    Honeycutt, William
    Kappos, Ludwig
    Selmaj, Krzysztof
    Wolinsky, Jerry
    Belachew, Shibeshih
    Bernasconi, Corrado
    Buffels, Regine
    Garren, Hideki
    Wei, Wei
    Traboulsee, Anthony
    NEUROLOGY, 2017, 88
  • [44] IMMUNOLOGICAL CORRELATES OF DISEASE-ACTIVITY IN MULTIPLE-SCLEROSIS PATIENTS TREATED WITH GAMMA-INTERFERON
    PANITCH, HS
    HIRSCH, RL
    SCHINDLER, J
    JOHNSON, KP
    ANNALS OF NEUROLOGY, 1986, 20 (01) : 124 - 124
  • [45] Immunological patterns identifying disease course and evolution in multiple sclerosis patients
    Furlan, R
    Rovaris, M
    Boneschi, FM
    Khademi, M
    Bergami, A
    Gironi, M
    Deleidi, M
    Agosta, F
    Franciotta, D
    Scarpini, E
    Uccelli, A
    Zaffaroni, M
    Kurne, A
    Comi, G
    Olsson, T
    Filippi, M
    Martino, G
    JOURNAL OF NEUROIMMUNOLOGY, 2005, 165 (1-2) : 192 - 200
  • [46] Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE)
    Smoot, Kyle
    Marginean, Horia
    Gervasi-Follmar, Tiffany
    Chen, Chiayi
    Repovic, Pavle
    Cohan, Stanley
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (08) : 956 - 966
  • [47] Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience
    Nasello, Martina
    Zancan, Valeria
    Rinaldi, Virginia
    Marrone, Antonio
    Renie, Roberta
    Diamant, Selene
    Marconi, Martina
    Le Mura, Lorenzo
    Salvetti, Marco
    Buscarinu, Maria Chiara
    Bellucci, Gianmarco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (10)
  • [48] Freedom from disease activity in multiple sclerosis
    Havrdova, Eva
    Galetta, Steven
    Stefoski, Dusan
    Comi, Giancarlo
    NEUROLOGY, 2010, 74 (17) : S3 - S7
  • [49] Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis
    Giovannoni, G
    Lai, M
    Kidd, D
    Thorpe, JW
    Miller, DH
    Thompson, AJ
    Keir, G
    Feldmann, M
    Thompson, EJ
    BRAIN, 1997, 120 : 1 - 13
  • [50] Correlating immunological and magnetic resonance imaging markers of disease activity in multiple sclerosis
    Giovannoni, G
    Kieseier, B
    Hartung, HP
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 : S31 - S36
12345